Abstract
Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.
| Original language | English |
|---|---|
| Pages (from-to) | 225-233 |
| Number of pages | 9 |
| Journal | Progress in Brain Research |
| Volume | 180 |
| Issue number | C |
| DOIs | |
| State | Published - 2009 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neuroscience(all)
Cite this
Brain as an HIV sequestered site : Use of nanoparticles as a therapeutic option. / Destache, Christopher J.
In: Progress in Brain Research, Vol. 180, No. C, 2009, p. 225-233.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Brain as an HIV sequestered site
T2 - Use of nanoparticles as a therapeutic option
AU - Destache, Christopher J.
PY - 2009
Y1 - 2009
N2 - Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.
AB - Patients infected with human immunodeficiency virus (HIV) are at increased risk to develop neurocognitive problems. HIV crosses the blood-brain barrier (BBB) through a variety of means. Once within the brain tissue, HIV stimulates immunoactivation and inflammation that lead to neuronal loss. This review discusses the pathophysiology of HIV within the brain and the treatment modalities used to prevent neurocognitive problems from developing. Modalities that prevent antiretroviral drugs from crossing into the central nervous system and reducing viral load are also discussed. Finally, since drug penetration across the BBB is reduced, the use of nanoparticles as a treatment modality to increase BBB penetration may be an option worth further exploration.
UR - http://www.scopus.com/inward/record.url?scp=77953416319&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953416319&partnerID=8YFLogxK
U2 - 10.1016/S0079-6123(08)80012-X
DO - 10.1016/S0079-6123(08)80012-X
M3 - Article
VL - 180
SP - 225
EP - 233
JO - Progress in Brain Research
JF - Progress in Brain Research
SN - 0079-6123
IS - C
ER -